Mucin 1 (MUC1), as an oncogene, plays an important role in the diagnosis of lung cancer.
OBJECTIVE:
To establish a double-antibody sandwich enzyme-linked immune sorbent assay (ELISA) kit for the detection of serum MUC1 in lung cancer patients.
METHODS:
Commercial mouse anti-human MUC1 monoclonal antibody and rabbit anti-human MUC1 polyclonal antibody were used to construct a double-antibody sandwich ELISA kit. The serum MUC1 levels in peripheral blood of lung disease patients and healthy individuals were detected by the double-antibody sandwich ELISA kit and CA15-3 kit, respectively.
RESULTS:
A double-antibody sandwich ELISA kit was successfully constructed, and the sensitivity was up to 0.5 μ g/l. The cut-off value for the serum MUC1 levels in the peripheral blood was 1.98 μ g/l, the sensitivity was 62.5%, the specificity was 100% and the Youden index was 0.6250 when detected by the double-antibody sandwich ELISA kit, while the sensitivity was 18.75%, the specificity was 100% and the Youden index was 0.1875 when detected by CA15-3 kit.
CONCLUSION:
The double-antibody sandwich ELISA kit is superior to the CA15-3 kit in the detection of serum MUC1 in lung cancer patients, suggesting an attractive applying of the double-antibody sandwich ELISA kit in the early diagnosis of lung cancer.
SiegelR., MaJ.M., ZouZ.H. and JemalA., Cancer statistics, Ca-a Cancer Journal for Clinicians64 (2014), 9-29.
2.
International Early Lung Cancer Action Program Investigators, HenschkeC.I., YankelevitzD.F., LibbyD.M., PasmantierM.W., SmithJ.P. and MiettinenO.S., Survival of patients with stage I lung cancer detected on CT screening, New England Journal of Medicine355 (2006), 1763-1771.
3.
KufeD.W., Functional targeting of the MUC1 oncogene in human cancers, Cancer Biology & Therapy8 (2009), 1197-1203.
4.
KufeD.W., Mucins in cancer: function, prognosis and therapy, Nature Reviews Cancer9 (2009), 874-885.
5.
CascioS., ZhangL. and FinnO.J., MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-kappaB p65 and binding to cytokine promoters: importance of extracellular domain, Journal of Biological Chemistry286 (2011), 42248-42256.
6.
KhodarevN.N., PitrodaS.P., BeckettM.A., MacDermedD.M., HuangL., KufeD.W. and WeichselbaumR.R., MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer, Cancer Research69 (2009), 2833-2837.
7.
LapointeJ., LiC., HigginsJ.P., van de RijnM., BairE., MontgomeryK., FerrariM., EgevadL., RayfordW., BergerheimU., EkmanP., De MarzoA.M., TibshiraniR., BotsteinD., BrownP.O., BrooksJ.D. and PollackJ.R., Gene expression profiling identifies clinically relevant subtypes of prostate cancer, Proc Natl Acad Sci USA101 (2004), 811-816.
8.
WreesmannV.B., SieczkaE.M., SocciN.D., HezelM., BelbinT.J., ChildsG., PatelS.G., PatelK.N., TalliniG., PrystowskyM., ShahaA.R., KrausD., ShahJ.P., RaoP.H., GhosseinR. and SinghB., Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker, Cancer Research64 (2004), 3780-3789.
9.
PitrodaS.P., KhodarevN.N., BeckettM.A., KufeD.W. and WeichselbaumR.R., MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment, Proc Natl Acad Sci USA106 (2009), 5837-5841.
10.
WinterJ.M., TangL.H., KlimstraD.S., BrennanM.F., BrodyJ.R., RochaF.G., JiaX., QinL.X., D'AngelicaM.I., De MatteoR.P., FongY., JarnaginW.R., O'ReillyE.M. and AllenP.J., A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers, PLoS One7 (2012), e40157.
11.
AwayaH., TakeshimaY., YamasakiM. and InaiK., Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung, American Journal of Clinical Pathology121 (2004), 644-653.
12.
KairaK., OkumuraT., NakagawaK., OhdeY., TakahashiT., MurakamiH., NaitoT., EndoM., KondoH., NakajimaT. and YamamotoN., MUC1 expression in pulmonary metastatic tumors: A comparison of primary lung cancer, Pathology & Oncology Research18 (2012), 439-447.
13.
WangX.F., WuY.H., WangM.S. and WangY.S., CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause, Asian Pacific Journal of Cancer Prevention15 (2014), 363-368.
14.
MolinoA., ColombattiM., BonettiF., ZardiniM., PasiniF., PeriniA., PelosiG., TridenteG., VeneriD. and CettoG.L., A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow, Cancer67 (1991), 1033-1036.
15.
RossA.A., CooperB.W., LazarusH.M., MackayW., MossT.J., CiobanuN., TallmanM.S., KennedyM.J., DavidsonN.E. and SweetD., Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques, Blood82 (1993), 2605-2610.
16.
FerreiraC.S., PapamichaelK., GuilbaultG., SchwarzacherT., GariepyJ. and MissailidisS., DNA aptamers against the MUC1 tumourmarker: Design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours, Analytical and Bioanalytical Chemistry390 (2008), 1039-1050.
17.
NicoliniA., TartarelliG., CarpiA., MetelliM.R., FerrariP., AnselmiL., ConteM., BertiP. and MiccoliP., Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases, BMC Cancer6 (2006), 269.
18.
DuffyM.J., Serum tumor markers in breast cancer: Are they of clinical value?Clinical Chemistry52 (2006), 345-351.
19.
MacDermedD.M., KhodarevN.N., PitrodaS.P., EdwardsD.C., PelizzariC.A., HuangL., KufeD.W. and WeichselbaumR.R., MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients, BMC Medical Genomics3 (2010), 16.
20.
WeberD.G., JohnenG., TaegerD., WeberA., GrossI.M., PeschB., KrausT., BrüningT. and GubeM., Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum, Biomark Insights5 (2010), 1-8.
21.
HamidS.S. and CheahS.H., Generation and characterization of a high-affinity monoclonal antibody for MUC1 measurement in breast cancer, Hybridoma (Larchmt)30 (2011), 137-143.
22.
UenY.H., LinS.R., WuC.H., HsiehJ.S., LuC.Y., YuF.J., HuangT.J. and WangJ.Y., Clinical significance of MUC1 and c-Met RT-PCR detection of circulating tumor cells in patients with gastric carcinoma, Clinica Chimica Acta367 (2006), 55-61.
23.
SituD., WangJ., MaY., ZhuZ., HuY., LongH. and RongT., Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer, Medical Oncology28 (2011), S596-S604.
24.
PowellE. and ChowL.Q., BLP-25 liposomal vaccine: A promising potential therapy in non-small-cell lung cancer, Expert Review of Respiratory Medicine2 (2008), 37-45.
25.
DemiragF., CakirE., BayizH. and Eren YaziciU., MUC1 and bcl-2 expression in preinvasive lesions and adenosquamous carcinoma of the lung, Acta Chirurgica Belgica113 (2013), 19-24.
26.
KimH.S., ParkY.H., ParkM.J., ChangM.H., JunH.J., KimK.H., AhnJ.S., KangW.K., ParkK. and ImY.H., Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer, Breast Cancer Research and Treatment18 (2009), 89-97.
27.
AtoumM., NimerN., AbdeldayemS. and NasrH., Relationships among serum CA15-3 tumor marker, TNM staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions, Asian Pacific Journal of Cancer Prevention13 (2012), 857-860.
28.
CroceM.V., Isla-LarrainM.T., DemichelisS.O., Segal-EirasA., GoriJ.R. and PriceM.R., Tissue and serum MUC1 mucin detection in breast cancer patients, Breast Cancer Research and Treatment81 (2003), 195-207.
29.
VelaiuthamS., TaibN.A., NgK.L., YoongB.K. and YipC.H., Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer? Asian Pacific Journal of Cancer Prevention9 (2008), 445-448.
